Novo Nordisks semaglutide (Wegovy) delivered impressive results against liver fibrosis and MASH (metabolic dysfunction-associated steatohepatitis) in a phase III trial, the company has reported
Medications make more sense for people with significant weight to lose for health reasons, those with type 2 diabetes or prediabetes where GLP-1 receptor agonists address both conditions simultaneously, individuals who have tried lifestyle changes and supplements without adequate results, and anyone whose healthcare provider recommends pharmaceutical intervention based on risk assessment
However, side effects can occur, and long-term safety data are limited
Kushwaha RN, Srivastava R, Mishra A, Rawat AK, Srivastava AK, Haq W, et al
Glow Blend is a multi-peptide research blend formulated for laboratory studies involving skin-related research models, collagen-focused research, and broader cosmetic peptide investigation